Bavarian Nordic, Mpox
Efficacy of Mpox Vaccine Wanes Within a Year, Studies Reveal
The escalating global Mpox outbreak has been met with a concerning revelation. Two distinct studies have indicated that the efficacy of Bavarian Nordic's vaccine, known as Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN),
Bavarian says mpox vaccine approved by EU regulator for adolescents
Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an outbreak in parts of Africa.
Mpox Vaccine: Twin Studies Show Bavarian Nordic’s Vaccine Efficacy Declines After One Year
Two separate studies have shown that the efficacy of Bavarian Nordic’s vaccine against the deadly infectious disease wanes “to undetectable levels” in 6-12 months. The vaccine, administered as a 2-dose injection given 4 weeks apart,
Study Shows Efficacy Of Mpox Vaccine Wanes To Undetectable Levels Within 6-12 Months
Two recent studies reveal that the efficacy of Bavarian Nordic's Mpox vaccine significantly declines within 6-12 months post-vaccination.
WHO clears Bavarian Nordic's vaccine for mpox, sets up access scheme
The World Health Organization and partners on Friday set up a scheme to help bring mpox vaccines, tests and treatments to the most vulnerable people in the world’s poorest countries, similar to efforts during the COVID-19 pandemic,
EMA approves Bavarian Nordic’s mpox vaccine for teenagers
The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the chances for its use in this age group in Africa. The label extension is via a type II variation – a route used when a major change is needed in the marketing authorisation for a medicine approved in Europe.
Global vaccine alliance GAVI to buy 500,000 doses of mpox vaccine
The global vaccine alliance Gavi says it will buy 500,000 doses of vaccine against mpox to fight outbreaks of the disease in ...
DPA International on MSN2d
EU extends authorization of the mpox vaccine to adolescents
The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17.
Mpox Vaccine Update Issued by WHO
The announcement marks the first mpox vaccine to be added to the WHO's prequalification list to facilitate timely access and ...
W.H.O. Authorizes Mpox Vaccine, Clearing Way for Use in Africa
The decision is a crucial step in getting shots to the Democratic Republic of Congo, the center of the outbreak.
World better positioned against mpox than for COVID: vaccine alliance
Lessons learned from the COVID pandemic have left the world in a much better position to tackle the current mpox epidemic ...
EU drug regulator approves Bavarian's mpox vaccine for adolescents, company says
The EU's drug regulator has approved Bavarian Nordic's mpox vaccine for use in adolescents aged 12 to 17 years, the company ...
Medscape2d
EMA Broadens Imvanex Vaccine Use to Teens as Mpox Cases Rise
With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.
Patients desperately wait for mpox vaccine at South Kivu Province clinic
Congo's South Kivu province is at the epicenter of the world’s latest mpox outbreak, in what the World Health Organization ...
WHO authorizes mpox vaccine, which should ease global access
The World Health Organization announced Friday it has authorized the use of an mpox vaccine, calling it an “important step” ...
Mpox: Three ongoing vaccine trials to watch
As the World Health Organization (WHO) has declared mpox an emergency, the Clinical Trials Arena team investigates ongoing ...